Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Basar, Rafet  [Clear All Filters]
2022
Fix SM, Forget M-A, Sakellariou-Thompson D, Wang Y, Griffiths TM, Lee M, Haymaker CL, Dominguez ALucía, Basar R, Reyes C, et al. CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling. J Immunother Cancer. 2022;10(7).
2021
Basar R, Uprety N, Ensley E, Daher M, Klein K, Martínez F, Aung F, Shanley M, Hu B, Gokdemir E, et al. Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. Cell Rep. 2021:109432.
Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, et al. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021:JCO2002608.
2020
Miao Q, Wang F, Dou J, Iqbal R, Muftuoglu M, Basar R, Li L, Rezvani K, Chen K. Ab initio Spillover Compensation in CyTOF Data. Cytometry A. 2020.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Kerbauy LNassif, Overman B, Thall P, Kaplan M, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382(6):545-553.
2019
Li L, Chen H, Marin D, Xi Y, Miao Q, Lv J, Banerjee PProsad, Shaim H, Daher M, Basar R, et al. A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. Blood Adv. 2019;3(23):4117-4130.